This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Akashi Therapeutics, Inc.
Drug Names(s): Tempostatin, delayed-release halofuginone
Description: HT-101, an orally bioavailable small molecule, is a potent and selective regulator of stromal cell activation, cell migration and Collagen type I synthesis.
Halofuginone hydrobromide was originally developed by Collgard Biopharmaceuticals.
Halo and Collgard
In December 2011, Halo Therapeutics announced that it arranged a deal with Collgard Biopharmaceuticals to acquire halofuginone. Under the terms of the agreement, Halo paid Collgard $500,000 upfront and will pay an additional $500,000 15 months later. Collgard will also receive an unspecified royalty upon commercialization of the drug.
DART and Akashi
In June 2014, DART Therapeutics, Inc. announced that it has changed its name to Akashi Therapeutics. Akashi Therapeutics combines the operations of DART and its subsidiary Halo Therapeutics, LLC, into a single entity.
Akashi and Grnenthal
In January 2016, Akashi Therapeutics announced a $100 million partnership with Grnenthal for a global drug development program for the investigational therapeutic HT-100 for the reduction of fibrosis and inflammation, and promotion of healthy muscle...See full deal structure in Biomedtracker
Partners: Grünenthal GmbH
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: